Oméprazole Arrow Lab (Omeprazole)

Omeprazole, the active ingredient in Oméprazole Arrow Lab, is a proton pump inhibitor presented as a strength‑form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Oméprazole Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.

Adverse reactions to omeprazole vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatotoxicity: elevated liver enzymes. - Hypomagnesemia: low serum magnesium levels. - Fracture risk: decreased bone mineral density with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects. - Assess renal and hepatic function: adjust use if impairment is present. - Review long‑term therapy: evaluate need after 8‑12 weeks. - Monitor for magnesium levels: especially in patients on prolonged therapy. - Caution in pregnancy: use only if benefit outweighs risk. - Avoid in known hypersensitivity to PPIs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk. - Atazanavir: decreased absorption leading to therapeutic failure. - Methotrexate (high dose): increased serum concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Digoxin: possible increase in serum levels. - Phenytoin: reduced plasma concentration. - Vitamin B12: decreased absorption with long‑term use.